Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Jody Aufrichtig | Co-Founder, Executive Chairman & Strategic Business Development Officer | 110.3k | -- | 1974 |
| Dr. Neil Maresky M.D. | CEO & Director | 231.23k | -- | 1965 |
| Mr. Warwick Ron Corden-Lloyd | Chief Financial Officer | 98.35k | -- | 1980 |
| Ms. Taryn Vos | General Counsel | -- | -- | -- |
| Ms. Mary-Elizabeth Gifford | Chief of Global Impact | -- | -- | -- |
Psyence Biomedical Ltd.
- Sector:
- Healthcare
- Industry: Biotechnology
Description
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
November 6, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission
October 8, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission